Banco BTG Pactual S.A. Has $571,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Banco BTG Pactual S.A. increased its stake in Teva Pharmaceutical Industries by 80.8%, owning a total of 37,131 shares valued at approximately $571,000.
• Several other institutional investors acquired new positions in Teva, contributing to a total institutional ownership of 54.05% of the company's stock.
• Teva's stock recently opened at $17.5550, with analysts setting a consensus price target of $24.71, reflecting positive outlooks despite a recent stock price decline of 2.8%.

Banco BTG Pactual S.A. grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 80.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,131 shares of the company's stock after buying an additional 16,598 shares during the quarter. Banco BTG Pactual S.A.'s holdings in Teva Pharmaceutical Industries were worth $571,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $54,000. Finally, Banque Cantonale Vaudoise bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $74,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Insiders Place Their Bets

In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,001 shares of company stock worth $996,958. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Stock Down 2.8%

TEVA stock opened at $17.5550 on Wednesday. The stock has a market capitalization of $20.13 billion, a P/E ratio of -109.72, a price-to-earnings-growth ratio of 1.07 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The firm has a 50-day moving average price of $16.69 and a 200-day moving average price of $16.25.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on TEVA. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.